Compare Docusign Inc (DOCU) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs TG Therapeutics Inc — how do they compare? Docusign Inc trades at $71.08 (market cap $13.35B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Docusign Inc is the larger of the two by market cap, and Docusign Inc is more actively traded (3,158,858 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and TG Therapeutics Inc for 16 Days on average.
| DOCU | TGTX | |
|---|---|---|
Market Cap | $13.35B | $8.16B |
Volume | 3,158,858 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $73.14 | $59.06 |
52-Week Low | $41.75 | $26.94 |
Typical Hold Time | 71 Days | 16 Days |
Enterprise Value | $12.76B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $71.43, up 3.67% with strong technical momentum and bullish moving averages. The company demonstrates robust revenue growth, improving from $2.1B in 2022 to $3.0B in 2025, with net income turning positive at $1.07B. Recent earnings beats and AI-driven contract processing capabilities support the bullish case, though valuation multiples remain elevated with a P/E of 43.55.
Outlook remains positive with continued earnings momentum and AI integration driving efficiency, but risks include insider selling activity and competitive pressures in the e-signature market. Analyst consensus is cautious with 64% hold ratings, though technical indicators suggest near-term strength with support at $70 and resistance at $72.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
